Lipoproteína (a) está associada com níveis basais de insulina em pacientes com Diabetes Mellitus tipo 2

Habib, Syed Shahid; Aslam, Muhammad; Shah, Syed Fayaz Ahmad; Naveed, Abdul Khaliq

doi:10.1590/s0066-782x2009000700006

Cited by 21 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies revealed a negative relationship between Lp(a) and serum insulin; studies speculated that higher Lp(a) levels among patients with a longer duration of type 2 diabetes may be attributed to lower plasma insulin levels in individuals. An in vitro study showed that insulin suppresses Apo(a) production in primary cynomolgus monkey hepatocytes [ 19 ]. This finding is inconsistent with our study, which showed a non-significant association between Lp(a) and serum insulin.…”

Section: Discussionmentioning

confidence: 99%

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients

Peela

Latiwesh²,

Elshaari³

et al. 2018

Cureus

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has high morbidity and results in increased risk of mortality mainly due to cardiovascular diseases. Different factors have been found to be responsible for the increased prevalence of coronary artery disease (CAD) in T2DM. One of these factors includes raised serum levels of lipoprotein(a) (Lp(a)). The present study was designed to evaluate the association of Lp(a) levels with T2DM in Libyan patients and find the degree of association between Lp(a), glycemic control, insulin, and lipid profile. The study included 100 T2DM patients, recruited from the Benghazi Center for Diagnosis and Treatment of Diabetes, and 30 apparently healthy age and sex-matched individuals, to serve as controls. All participants completed a questionnaire to obtain clinical information and medical history. Blood samples were collected and analyzed for Lp(a), fasting blood glucose (FBS), HbA1c, insulin, total cholesterol (TC), triglycerides (TAG), low-density lipoprotein c (LDL-c), and high-density lipoprotein c (HDL-c). The results from the comparison between the control and experimental groups showed that Lp(a) was significantly higher in diabetic patients. It showed the positive correlation with TC and LDL-c. On the contrary, it showed no significant correlations with glycemic control parameters nor insulin, TAG, HDL-c, body mass index (BMI), and blood pressor (BP). Cardiovascular disease (CVD) risk in type 2 diabetic patients could be dependent on risk factors other than LDL-c, which may not be an independent risk factor for the development and progression of atherogenesis in T2DM. Lp(a) may be a new metabolic syndrome risk factor, and it may be useful as a cardiovascular risk biomarker in future clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients

Peela

Latiwesh²,

Elshaari³

et al. 2018

Cureus

View full text Add to dashboard Cite

show abstract

“…Subjects with IFG yielded a lower risk (29%) of presenting elevated Lp(a) values in comparison to normoglycemic individuals. This behavior is intimately linked to the impact of insulin in the metabolism of Lp(a), where it has been attributed an inhibiting effect in the synthesis of Apo(a) in animal models [56], supported by inverse relationships observed between both molecules in population studies [57, 58]. Of all glycemic status subgroups, subjects with IFG presented the most augmented values of insulinemia, statistically different to those of the normoglycemics (19.23 ± 12.84 versus 14.17 ± 8.45 mg/dL; P < 0.05).…”

Section: Discussionmentioning

confidence: 99%

Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study

Bermúdez

Rojas

Salazar

et al. 2013

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. Lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular disease, yet its influence on metabolic syndrome (MS) is still controversial. The purpose of this study was to assess the impact generated by this diagnosis in serum Lp(a) concentrations. Materials and Methods. A total of 1807 subjects of both genders (55.3% women and 44.7% men) belonging to the Maracaibo City Metabolic Syndrome Prevalence Study were evaluated. Results were expressed as Mean ± SD, determining differences through Student's t-test and One-Way ANOVA test. Multiple logistic regression models were utilized for analyzing factors associated with elevated serum Lp(a) levels and MS. Total cholesterol and LDL-C were corrected according to Lp(a)-Cholesterol when necessary. Results. No differences were found in Lp(a) values between genders; P = 0,292. The association between MS and the classification of Lp(a) was statistically significant (χ 2 = 28.33; P < 0,0001), with greater levels in subjects with this diagnosis. In the univariate analysis, subjects with each of the separate diagnostic criteria showed higher serum Lp(a) concentrations, except for hyperglycemia. Conclusions. Lp(a) values exhibit important variations regarding MS and each of its components. Impaired fasting glucose appeared as a protecting factor against elevated Lp(a) concentrations, whereas its association with LDL-C and hs-CRP suggests a potential pro-inflammatory role.

show abstract

“…However, previous reports regarding Lp(a) levels and T2D are conflicting [7]. Decreased Lp(a) levels in response to hyperinsulinemia [8,9] and a negative relationship between Lp(a) levels and the incidence of T2D have been reported previously [10,11]. In contrast, some studies have shown a strong positive association between T2D and elevated Lp(a) levels [12,13].…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein(a) is not related to markers of insulin resistance in pregnancy

Todoric

Handisurya

Leitner

et al. 2013

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundDyslipidemia, a major risk factor for cardiovascular disease is a common finding in patients with type 2 diabetes and among women with gestational diabetes. Elevated levels of lipoprotein(a) [Lp(a)] are linked to increased risk of cardiovascular disease. However, its relationship with insulin resistance, type 2 diabetes and gestational diabetes is controversial and unproven. Here we aimed to clarify whether Lp(a) levels are associated with insulin sensitivity in pregnancy.MethodsSixty-four women with gestational diabetes and 165 with normal glucose tolerance were enrolled in the study. Fasting Lp(a) serum levels were measured in all women at 24–28 weeks of gestation.ResultsIn pregnancy, there was no significant difference in serum Lp(a) concentrations between the two groups. Its level did not correlate with markers of insulin resistance (HOMA-IR), insulin sensitivity (HOMA-S%), pancreatic beta-cell function (HOMA-B%) and insulin sensitivity in dynamic conditions (OGIS). In addition, fasting glucose and insulin levels and those throughout an oral glucose tolerance test were independent of Lp(a) concentrations in our study group.ConclusionsLp(a) levels in pregnant women do not differ with respect to the presence or absence of gestational diabetes. Although influenced by some components of the lipid profile, such as triglycerides and HDL-C, insulin resistance in pregnancy is not affected by Lp(a).

show abstract

Lipoproteína (a) está associada com níveis basais de insulina em pacientes com Diabetes Mellitus tipo 2

Abstract: SummaryBackground: It has not been clearly established whether insulin resistance/deficiency leads directly to atherogenesis or through its association with other risk factors such as Lipoprotein(a) [Lp(a)].

Cited by 21 publications

References 31 publications

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients

Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients

Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study

Lipoprotein(a) is not related to markers of insulin resistance in pregnancy

Contact Info

Product

Resources

About